About: A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) wüsseschaftlicher Artikel, wo im Johr 2000 veröffentlicht worden isch (gsw) наукова стаття, опублікована в січні 2000 (uk) im Januar 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 2000 (ast) articolo scientifico (pubblicato il 2000) (it) artikull shkencor i botuar më 01 janar 2000 (sq) scientific article published on 01 January 2000 (en)
publication date	wds:Q73348058-11FA25F3-8767-4033-A8BD-11B72260A8E0
publication date	2000-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q73348058-46677294-1D07-4275-BE46-8C7E2D71FDE0 wds:Q73348058-5EB18494-7324-4EE6-AF73-A4B9A2C7A1F5 wds:Q73348058-8008395E-FA2E-44AC-8D74-73391374D687 wds:Q73348058-B08326DB-C1E3-430C-AA02-95E53CD4F9BF wds:Q73348058-C6A16F46-AF00-4B3F-B322-BA6AFC2F226A wds:Q73348058-D3A4B02A-CE96-4CFC-B4FC-775F44B52B8F wds:Q73348058-F940D2EB-3BC3-4195-AFDC-876989B0DE2B
author name string	K D Bardhan E Schütz G Bodemar A Heath J G Mills H Geldof L A Jacques
rdfs:label	A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (en) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (nl) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (sq)
skos:prefLabel	A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (en) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (nl) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (sq)
name	A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (en) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (nl) A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (sq)
title	wds:Q73348058-0B1FABD6-23FE-48B0-9A7D-D770E3BB23D1
title	A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (en)
page(s)	wds:Q73348058-EAE610F1-8248-416E-8D58-7DB55AE257B1
page(s)	23-34
instance of	wds:Q73348058-102FD37C-E331-4CC5-B778-0BB2EB23CBC4
instance of	scholarly article
main subject	wds:Q73348058-5023AAFC-3D82-45B6-B2BF-94A49C6C0D06 wds:Q73348058-810667C6-7E76-4DE8-9A43-67B5C450BB60 wds:Q73348058-B4AFEC5F-864C-4CCF-B612-FEEE55F55031
main subject	alosetron placebo irritable bowel syndrome
PubMed ID	wds:Q73348058-1AB0D53C-9DF6-4A24-9BE3-6999F8412BB6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10632642
PubMed ID	10632642
published in	wds:Q73348058-B170EDBC-E099-47B9-B3A1-D33686184AEF
published in	Alimentary Pharmacology & Therapeutics
issue	wds:Q73348058-CD038BB1-3335-4EB9-AC55-84E9AB5E0839
volume	wds:Q73348058-B5E4A5BA-57A9-4086-B755-DA4460C1527F
issue	1
volume	14
DOI	wds:Q73348058-4BC4C0CF-7849-4229-9F56-5EBDBEF2A1B1
DOI	http://dx.doi.org/10.1046/J.1365-2036.2000.00684.X
DOI	10.1046/J.1365-2036.2000.00684.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73348058
is cites work of	Serotonergic modulation of visceral sensation: lower gut. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review Guidelines on the irritable bowel syndrome: mechanisms and practical management. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes Current insights in to the pathophysiology of Irritable Bowel Syndrome Antibiotics for irritable bowel syndrome: rationale and current evidence New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial Targeted therapies for diarrhea-predominant irritable bowel syndrome Post-infectious irritable bowel syndrome Role of serotonin in the pathophysiology of the irritable bowel syndrome Pharmacological treatment of irritable bowel syndrome: a critical assessment Diagnosis and treatment of irritable bowel syndrome: state of the art. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study Antibiotics for the treatment of irritable bowel syndrome Alosetron Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Irritable bowel syndrome Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome Current gut-directed therapies for irritable bowel syndrome Sex, gender, and irritable bowel syndrome: making the connections Serotonergic modulating drugs for functional gastrointestinal diseases Pharmacotherapy for intestinal motor and sensory disorders An Initial Attack of Urinary Stone Disease Is Associated with an Increased Risk of Developing New-Onset Irritable Bowel Syndrome: Nationwide Population-Based Study Reply Comparison of breath testing with fructose and high fructose corn syrups in health and IBS. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Pharmacology of serotonin: what a clinician should know. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D) Irritable bowel syndrome: evaluation and treatment An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Updates on treatment of irritable bowel syndrome Clinical study on the treatment of gastroesophageal reflux by acupuncture Gastrointestinal functional bowel disorders: new therapies Drugs and Medical Devices: Adverse Events and the Impact on Women's Health Novel Therapies in IBS-D Treatment

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software